2 Information about brigatinib

Marketing authorisation indication

2.1 Brigatinib (Alunbrig, Takeda) has a marketing authorisation for 'the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer (NSCLC) previously not treated with an ALK inhibitor'.

Dosage in the marketing authorisation

2.2 The dosage schedule is available in the summary of product characteristics.


2.3 The list price of brigatinib is £4,900.00 (excluding VAT; BNF accessed November 2020) for the:

  • starter pack (7 tablets at 90 mg plus 21 tablets at 180 mg)

  • 28‑tablet pack at 180 mg.

    The company has a commercial arrangement. This makes brigatinib available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.

  • National Institute for Health and Care Excellence (NICE)